What is CING's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CING?

P/E (TTM) is n/a and 52-week range is $3.16 to $11.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CING figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CING?

The company profile lists net income (TTM) near -$54M, EPS (TTM) near -$3.68 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cingulate Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Kansas City, Kansas, US, 14.5M shares outstanding, ISIN US17248W3034 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cingulate Inc

$CING

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 14 full-time employees. The company went IPO on 2021-10-07. The firm offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. The company develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). The company also develops CTx-2103 (buspirone), for the treatment of anxiety.

Employees

Website

www.cingulate.com/

IPO

2021-10-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US17248W3034

Headquarters

Kansas City, Kansas, US

Shares outstanding

14.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

12.61%

Browse other companiesFree AI scores and summaries for more stocks